• Aucun résultat trouvé

[PDF] Top 20 MYEOV is a prognostic factor in multiple myeloma.

Has 10000 "MYEOV is a prognostic factor in multiple myeloma." found on our website. Below are the top 20 most common "MYEOV is a prognostic factor in multiple myeloma.".

MYEOV is a prognostic factor in multiple myeloma.

MYEOV is a prognostic factor in multiple myeloma.

... overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA ...al. MYEOV, a gene at 11q13, is coamplified with ... Voir le document complet

35

CD200 is a new prognostic factor in multiple myeloma.

CD200 is a new prognostic factor in multiple myeloma.

... gene in multiple myeloma cells (MMC) of 112 patients with newly-diagnosed multiple myeloma ...call) in 22% and 78% of MMC, respectively. The CD200 gene is not expressed ... Voir le document complet

13

Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.

Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.

... Introduction Multiple myeloma (MM) is a B cell neoplasia characterized by the accumulation of clonal malignant plasma cells in the bone ...marrow. In the majority of patients, ... Voir le document complet

38

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.: IGF-1 is the major growth factor on myeloma

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.: IGF-1 is the major growth factor on myeloma

... Introduction Multiple myeloma (MM) is a clonal plasma-cell ...disorder. Multiple myeloma cells (MMC) from almost all patients harbor chromosomal abnormalities by FISH 1,2 and ... Voir le document complet

42

Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer.

Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer.

... modulated in cyclin A2–deficient CECs at the protein level, we took advantage of the inducible Cre mouse model (VilCreERT2 Ccna2 fl/fl ...expression in VilCreERT2 Ccna2 fl/fl mice (Figure 5B, middle and ... Voir le document complet

21

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

... LEN in combination with HIF-1 α inhibition significantly reduced the expression of p-ERK1/2, total Casp-3, HK2 and the p27 inhibitor, SKP2 (Figure ...the in vivo anti- tumoral effect of LEN through ... Voir le document complet

5

The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.

The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.

... APRIL is able to upregulate Bfl-1/A1 in XG-13 ...found in BMPC despite hallmarks of NF-κB activation, in association with data showing that Bfl-1/A1 was poorly expressed and not inducible ... Voir le document complet

34

Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy

Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy

... L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignemen[r] ... Voir le document complet

13

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

... lysed in 10 mM Tris-HCl (pH ...to a nitrocellulose membrane (Schleicher and Schuell, Kassel, ...temperature in 140 mM NaCl, 3 mM KCl, 25 mM Tris-HCl (pH ...with a rabbit polyclonal ... Voir le document complet

43

Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation.

Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation.

... human myeloma cell lines (A) Cell surface expression of INSR was determined by flow cytometry using PEconjugated anti-INSR ...as a standard. (C) Box plots of gene expression signal for INSR in ... Voir le document complet

15

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.

... used in this study was developed with Affymetrix microarrays. It is of note that not all Affymetrix probe sets work “properly”, ...show a 100% sensitivity and specificity. This is because ... Voir le document complet

10

Expressed fusion gene landscape and its impact in multiple myeloma

Expressed fusion gene landscape and its impact in multiple myeloma

... pathways is supported, but also modified by the fact that all Ig translocations, not only IGH, are ...fusion, a novel recurrent partner gene, B2M was identified, fusing with either IGH and IGK and which was ... Voir le document complet

11

Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

... Research in Biotherapy, Montpellier, France, 3 Medizinische Klinik V, Universita¨tsklinikum Heidelberg and Nationales Centrum fu¨r Tumorerkrankungen, Heidelberg, Germany, 4 Universite´ MONTPELLIER1, UFR Me´decine, ... Voir le document complet

14

Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

... AREG, a member of the EGF family, is overexpressed in MM ...AREG is expressed by myeloma cells and can be both an autocrine factor for the myeloma cells themselves and ... Voir le document complet

36

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

... Although a number of other cancer cell lines have high levels of DEPTOR (data not shown), as a class only multiple myelomas appear to consistently overexpress ...overexpression in MM cells may ... Voir le document complet

15

Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART

Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART

... as a measure of adherence has been previously validated, [37,46-49] it may not account for individuals who received their medication but did not actually take ...it. In the two situations described ... Voir le document complet

9

Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.: DNA microarrays in multiple myeloma

Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.: DNA microarrays in multiple myeloma

... Introduction Multiple myeloma (MM) is a B cell neoplasia that affects 15 000 new patients per year in Europe and 15 000 in the United ...It is characterized by the ... Voir le document complet

24

Programmed death–ligand 1 and vimentin: A tandem marker as prognostic factor in NSCLC

Programmed death–ligand 1 and vimentin: A tandem marker as prognostic factor in NSCLC

... EMT is characterized by diminished epithelial characteristics and enhanced mesenchymal ...parameters in a variety of cancers including NSCLC [ 9 ]. Vimentin, a canonical marker and actor of ... Voir le document complet

14

Thymosin beta4 in multiple myeloma: friend or foe

Thymosin beta4 in multiple myeloma: friend or foe

... what is seen in solid tumors, we found in MM cells a decreased expression of Tβ4 compared to their normal counterpart (plasma ...some prognostic value; patients with a high Tβ4 ... Voir le document complet

5

Genomics of Multiple Myeloma

Genomics of Multiple Myeloma

... fined in 2006 and identified seven subclasses of myelomas. 12 The first group is defined by the translocation t(4;14), which is identified by overexpression of the MMSET and/or FGFR3 ...group is ... Voir le document complet

7

Show all 10000 documents...